Cancer clinical trials in the region Nouvelle-Aquitaine

232 currently recruiting clinical trials
Region Nouvelle-Aquitaine

Early Access Lung cancer
NSCLC (Non-Small Cell Lung Cancer) Locally Advanced Metastatic EGFR Targeted therapy
Systemic Treatment-Naive
Janssen
Early Access Lung cancer
NSCLC (Non-Small Cell Lung Cancer) Locally Advanced Metastatic EGFR None Systemic Treatment-Naive
Janssen
Early Access Lung cancer
NSCLC (Non-Small Cell Lung Cancer) Non-squamous NSCLC Locally Advanced EGFR None Chemotherapy Radiotherapy
AstraZeneca
Early Access Lung cancer
NSCLC (Non-Small Cell Lung Cancer) Localized ALK None Systemic Treatment-Naive Surgery
Hoffmann-La Roche
Early Access Lung cancer
NSCLC (Non-Small Cell Lung Cancer) Localized PDL1 Positive (1% <= X < 25%) PDL1 Positive (25% <= X < 50%) PDL1 Positive (>= 50%) None Systemic Treatment-Naive
ALK EGFR
Bristol-Myers Squibb
Early Access Lung cancer
SCLC (Small Cell Lung Cancer) Localized Locally Advanced None Chemotherapy Radiotherapy Chemotherapy Radiotherapy
AstraZeneca
Phase 3 Lymphoma Chronic lymphocytic leukemia
#NCT06428019
B cell lymphoma Lymphocytic lymphoma > 60 ml/min 50-60 ml/min 30-50 ml/min Systemic Treatment-Naive
Centre Hospitalier de la Côte Basque (Bayonne)
Abbvie
Phase 3 Prostate cancer
#NCT06120491
Metastatic Hormone-sensitive Surgery Radiotherapy Systemic Treatment-Naive
Centre Hospitalier​ Universitaire de Bordeaux (Bordeaux), Centre Hospitalier Universitaire de Poitiers - Site de la Milétrie (Poitiers), Centre Hospitalier de la Côte Basque (Bayonne)
AstraZeneca
Phase 3 Endometrial cancer
#NCT06132958
Endometrioid adenocarcinoma Serous adenocarcinoma Clear cell carcinoma Dedifferentiated and undifferentiated endometrial ... Carcinosarcoma Locally Advanced Metastatic 1 2 3 or more Immunotherapy Chemotherapy
Antibody Drug Conjugates (ADC)
Institut Bergonié (Bordeaux)
Merck Sharp & Dohme LLC
Phase 3 Lymphoma
#NCT06191744
B cell lymphoma Follicular lymphoma CD20 None Systemic Treatment-Naive
Centre Hospitalier Robert Boulin (Libourne)
Genmab